
|Videos|December 15, 2017
Glasdegib Active in Heavily Pretreated Myelofibrosis
Author(s)Aaron Gerds, MD
This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Advertisement
In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Gerds gave a presentation on this study (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
2
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
3
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
4
177Lu-Dotatate Combo Shows Consistent Efficacy Across GEP-NET Subgroups
5














































